# Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI

> **NCT01005251** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 661 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease
- Heartburn
- Regurgitation

## Interventions

- **DRUG:** lesogaberan (AZD3355)
- **DRUG:** lesogaberan (AZD3355)
- **DRUG:** lesogaberan (AZD3355)
- **DRUG:** lesogaberan (AZD3355)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01005251
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 661 (ACTUAL)
- **Last updated:** 2011-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01005251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01005251, "Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01005251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*